Agomelatine for Depression in Schizophrenia: A Case-Series
Our findings provide initial evidence that agomelatine is safe and efficacious in treating depressive symptoms in patients with schizophrenia. Furthermore, agomelatine seems to be effective for the treatment of negative symptoms. Randomized controlled trials are necessary to confirm these first observations.
Authors
- H. Russmann
- Jochen Mutschler (ORCID: https://orcid.org/0000-0002-3710-356X)
- Nicolas Rüsch (ORCID: https://orcid.org/0000-0003-4543-1560)
- Herdis Schönfelder
- Wulf Rössler (ORCID: https://orcid.org/0000-0003-0049-4533)
- Annette Beatrix Brühl (ORCID: https://orcid.org/0000-0003-4704-4986)
- Uwe Herwig (ORCID: https://orcid.org/0000-0002-9933-5171)
- Martin Grosshans
Institutions
- University of Zurich (CH)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
Publication Details
- Journal
- Psychopharmacology Bulletin
- Published
- 2025-08-12
- DOI
- https://doi.org/10.64719/pb.4060
- Citations
- 5
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00